Statements (115)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:gene_therapy
|
| gptkbp:acquired_by |
gptkb:Novartis_AG
|
| gptkbp:aims_to |
improve patient outcomes
transform patient care |
| gptkbp:aims_to_improve |
gptkb:muscular_dystrophy
Patient Outcomes |
| gptkbp:clinical_trial |
SMA Treatment
|
| gptkbp:collaborates_with |
Academic Institutions
academic institutions |
| gptkbp:conducts |
clinical research
|
| gptkbp:contributes_to |
Scientific Research
|
| gptkbp:dedicated_to |
Patient Safety
patient safety Transforming Lives advancing science |
| gptkbp:develops |
gptkb:Zolgensma
gptkb:Luxturna |
| gptkbp:develops_therapies_for |
Rare Diseases
|
| gptkbp:employs |
gptkb:biotechnology
gptkb:scientists |
| gptkbp:engages_in |
gptkb:Clinical_Trials
|
| gptkbp:focuses_on |
gptkb:gene_therapy
gptkb:Gene_Therapy rare diseases |
| gptkbp:founded_in |
gptkb:2018
|
| gptkbp:has_achieved |
milestones in gene therapy
|
| gptkbp:has_collaborated_with |
biopharmaceutical companies
|
| gptkbp:has_collaborations_with |
Biotech Companies
|
| gptkbp:has_developed |
gene editing technologies
|
| gptkbp:has_headquarters_in |
gptkb:Cambridge,_Massachusetts
|
| gptkbp:has_impact_on |
Healthcare Industry
|
| gptkbp:has_part |
clinical trials
Research Facilities manufacturing facilities |
| gptkbp:has_partnerships_with |
Non-Profit Organizations
|
| gptkbp:has_product |
gptkb:Zolgensma
|
| gptkbp:has_received |
FDA approval
EMA approval |
| gptkbp:has_research_focus |
Gene Editing
|
| gptkbp:headquartered_in |
gptkb:Boulder,_Colorado
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novartis Gene Therapies
|
| gptkbp:investment |
gptkb:Research_and_Development
research and development |
| gptkbp:is_active_in |
Global Markets
global markets clinical development |
| gptkbp:is_aleader_in |
Gene Therapy Field
|
| gptkbp:is_committed_to |
ethical practices
Ethical Practices |
| gptkbp:is_engaged_in |
gptkb:Community_Outreach
patient education Global Health Initiatives Public Health Campaigns collaborative research regulatory affairs |
| gptkbp:is_focused_on |
Innovative Solutions
innovation Sustainable Practices personalized medicine Long-Term Outcomes long-term outcomes Patient-Centric Solutions patient-centric approaches |
| gptkbp:is_involved_in |
gptkb:activists
Regenerative Medicine Patient Education community outreach patient advocacy biomedical research global health initiatives Regulatory Submissions healthcare innovation Health Policy Advocacy Global Collaborations clinical trials for rare diseases |
| gptkbp:is_known_for |
Innovative Research
innovative therapies transformative therapies Transformative Therapies Gene Therapy Innovations |
| gptkbp:is_part_of |
gptkb:Novartis_Gene_Therapies_Division
gptkb:Novartis_Pharmaceuticals_Corporation gptkb:Novartis_Group biotechnology industry Novartis Gene Therapies Network global healthcare community |
| gptkbp:is_recognized_by |
gptkb:healthcare_professionals
Industry Awards |
| gptkbp:is_recognized_for |
scientific excellence
Scientific Contributions therapeutic advancements Pioneering Research |
| gptkbp:is_supported_by |
gptkb:investors
gptkb:scientific_research Scientific Community Patient Testimonials Clinical Evidence |
| gptkbp:offers |
gptkb:Zolgensma
Innovative Therapies |
| gptkbp:part_of |
gptkb:Novartis_AG
|
| gptkbp:partnership |
Healthcare Providers
healthcare providers |
| gptkbp:promotes |
Patient Access
|
| gptkbp:receives_funding_from |
gptkb:investors
|
| gptkbp:regulatory_compliance |
FDA Approval
|
| gptkbp:strategic_goals |
Innovation and Growth
|
| gptkbp:targets |
Genetic Disorders
neurological disorders ocular disorders |
| gptkbp:uses |
AAV9 vector
|
| gptkbp:utilizes |
gptkb:AAV_technology
Advanced Technology |
| gptkbp:bfsParent |
gptkb:Ave_Xis
gptkb:Novartis_Pharmaceuticals_Corporation |
| gptkbp:bfsLayer |
6
|